The ECPC is particularly looking for patients from the UK to complete the survey but all are welcome to take part.
What are biomarkers?
A biomarker is a molecule or a gene, the presence or absence of which can be used to characterise a particular cancer type. Biomarkers are typically tested for in order to help physicians choose the right therapy, depending on the patient’s genetic profile (e.g., in breast cancer, whether or not a breast cancer patient tests positive for HER2 can inform if the drug Trastuzumab is appropriate/suitable for the patient). Biomarker testing may also be called “molecular testing” or “genetic testing” in clinical practice with the same meaning.¹
For appendix cancer patients, whether the patient tests positive for KRAS can inform if the drug AMG 510 may be appropriate/suitable for the patient.